A*STAR Bioinformatics Institute (A*STAR BII)

A*STAR’s steady investments in R&D and talent create the ideal conditions for impactful science, says its Chief Executive Officer Frederick Chew.

Contrary to popular belief, a new A*STAR study shows that HIV mutations are far from random, emerging at specific locations at specific rates.

A portable, low-cost spectrophotometer could free up scientists to perform routine experiments outside the lab.

Tracking how SARS-CoV-2 interacts with host cell receptors during infections may give us new ideas for COVID-19 drug targets.

From expanding the genetic alphabet to uncovering antibiotics hidden in silent genes, A*STAR’s researchers are wielding the tools of synthetic biology to improve our lives in surprising ways.

The discovery of a new, highly conserved druggable site on the HIV reverse transcriptase could turn the tide in the wake of growing drug resistance.

Low levels of sugar entering into pancreatic cells may be the culprit behind insulin secretion defects in early-onset diabetes.

In a classic case of double trouble, the binding of SARS-CoV-2’s spike protein to bacterial lipopolysaccharide supercharges inflammation in COVID-19 patients.

The detailed structure of a testosterone-regulating enzyme is helping researchers to design better drugs for diseases such as prostate cancer.

Using newly-developed tools, researchers discover that age and social anxiety are amongst the unique determinants of civility in Singapore.

A genetic discovery reveals why some aggressive carcinomas do not respond to standard treatment and suggest a more effective option.

Exploiting a mutation in a key tumor-fighting protein may provide a new opportunity to treat aggressive lung cancers.